Geode Capital Management
CYTO

Geode Capital Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Geode Capital Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-47
Closed -$5K – 4946
2022
Q3 		$5K Hold
47
– – ﹤0.01% 5014
2022
Q2 		$9K Hold
47
– – ﹤0.01% 4989
2022
Q1 		$20K Hold
47
– – ﹤0.01% 4931
2021
Q4 		$34K Hold
47
– – ﹤0.01% 4908
2021
Q3 		$37K Hold
47
– – ﹤0.01% 4807
2021
Q2 		$67K Sell
47
-7
-13% -$9.61K ﹤0.01% 4623
2021
Q1 		$75K Hold
54
– – ﹤0.01% 4351
2020
Q4 		$56K Buy
+54
New +$34.8K ﹤0.01% 4153
2019
Q2 		– Sell
-11
Closed -$31K – 4247
2019
Q1 		$31K Buy
11
+9
+450% +$28.9K ﹤0.01% 4067
2018
Q4 		$8K Hold
2
– – ﹤0.01% 4132
2018
Q3 		$6K Hold
2
– – ﹤0.01% 4119
2018
Q2 		$14K Buy
+2
New +$21.1K ﹤0.01% 4049
2018
Q1 		– Hold
0
– -$7K – 4087
2017
Q4 		– Hold
0
– – – 4015
2017
Q3 		– Hold
0
– – – 4041
2017
Q2 		– Hold
0
– – – 4079
2017
Q1 		– Hold
0
– – – 4053
2016
Q4 		– Hold
0
– – – 4012
2016
Q3 		– Hold
0
– – – 3978
2016
Q2 		– Hold
0
– – – 3888
2016
Q1 		– Hold
0
– – – 3952

Other funds holding CYTO

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SCA
Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

Geode Capital Management's CYTO Position: Q4 2022 in Review

Geode Capital Management sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2022, closing a stake of 47 shares — an estimated $5K sold.

Geode Capital Management first reported a position in CYTO in Q2 2018 and held it in 12 quarters. The position peaked at $75K in Q1 2021. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2022.

  • Geode Capital Management reported no remaining Altamira Therapeutics Ltd position as of Q4 2022 after selling out during the quarter.
  • Geode Capital Management sold 47 Altamira Therapeutics Ltd shares in Q4 2022, an estimated $5K.
  • Geode Capital Management first reported a position in Altamira Therapeutics Ltd in Q2 2018 and held it in 12 quarters.
  • Geode Capital Management's Altamira Therapeutics Ltd position peaked at $75K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2022.

Based on Geode Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.